Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034
NCT00478725
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
10
Enrollment
INDUSTRY
Sponsor class
Conditions
Carcinoma, Renal Cell
Interventions
DRUG:
GW786034, oral
DRUG:
GW786034, IV
DRUG:
GW786034, radiolabeled oral
Sponsor
GlaxoSmithKline